EUVIMEDSkopri EUVIMED
Multizentrische StudieBeobachtungsstudieVergleichsstudie

Clinical Outcomes According to the Extent of Atherosclerotic Disease in Female Patients Undergoing Transcatheter Aortic Valve Replacement: An Analysis From the WIN‐TAVI Registry

Benjamin Bay iD, Mauro Gitto, Samantha Sartori iD, Birgit Vogel, Didier Tchetche, Anna Sonia Petronio, Julinda Mehilli, Francesca Maria Di Muro, Thierry Lefevre, Patrizia Presbitero, Piera Capranzano iD, Angelo Oliva iD and 19 more

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.31395 ↗

At a glance

Multizentrische Studie in Catheterization and Cardiovascular Interventions, 2025. Written by Benjamin Bay and 30 co-authors. Institution: The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Major MEDLINE topics: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Aortic Valve, Atherosclerosis. Cited 1 times so far (Crossref); 24 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Limited data exist on the impact of polyvascular disease (PolyVD) on clinical outcomes in female patients undergoing transcatheter aortic valve replacement (TAVR). We therefore sought to investigate clinical outcomes in women with versus without PolyVD undergoing TAVR.

Methods

Female participants from the multicentre Women's International Transcatheter Aortic Valve Implantation (WIN‐TAVI) registry were categorized based on the presence or absence of PolyVD. The PolyVD population was defined as the presence of atherosclerotic disease affecting ≥ 2 arterial systems from coronary, cerebral, or lower limb peripheral vessels, whilst patients with either no atherosclerosis or atherosclerotic disease in one vascular system were included in the non‐PolyVD population. The primary endpoint was the Valve Academic Research Consortium‐2 consensus (VARC‐2) efficacy endpoint at 1 year, whilst secondary endpoints included VARC‐2 safety events, VARC‐2 major bleeding and major vascular complications. Cox regression analysis were computed adjusting for various cofounders.

Results

Among 996 participants, 543 (54.5%) had PolyVD, while 453 (45.5%) did not. Across the subgroups no differences in age was noted, whilst patients with PolyVD were more likely to have a history of hypercholesterolemia and a previous cardiac surgery. The incidence of the primary endpoint was higher in the PolyVD group (19.4%) compared to the non‐PolyVD group (13.3%, p log‐rank = 0.014), though the difference was attenuated after multivariable adjustments ( p = 0.093). Of note, no statistically significant differences concerning incident VARC‐2 safety events, VARC‐2 major bleeding and major vascular complications were noted according to PolyVD status.

Conclusion

PolyVD is a common comorbidity and is associated with elevated rates of adverse clinical events, but no increase in safety events, vascular complications, or bleeding among women undergoing TAVR.

Subjects

MeSH terms (MEDLINE)

Transcatheter Aortic Valve ReplacementAortic Valve StenosisAortic ValveAtherosclerosisPeripheral Arterial DiseaseHumansFemaleRegistriesTreatment OutcomeAged, 80 and overRisk FactorsAgedTime FactorsSex FactorsRisk AssessmentSeverity of Illness Index

Author keywords

TAVRoutcomepolyvascular diseasewomen

Authors and institutions

  • The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Clinique Pasteur, Toulouse, France.
  • AOUP Cisanello, University Hospital, Pisa, Italy.
  • Medizinische Klinik I, Landshut-Achdorf Hospital, Landshut, Germany.

ORCID profiles: Benjamin Bay, Samantha Sartori, Piera Capranzano, Angelo Oliva, Alessandro Iadanza, Pier Pasquale Leone, Gennaro Sardella, Nicolas M van Mieghem, Daniela Trabattoni, Maria-Cruz Ferrer-Gracia, Yusuke Watanabe, George D Dangas, Roxana Mehran

Cite

APA

Bay, B., Gitto, M., Sartori, S., Vogel, B., Tchetche, D., Petronio, A. S., Mehilli, J., Di Muro, F. M., Lefevre, T., Presbitero, P., Capranzano, P., Oliva, A., Iadanza, A., Leone, P. P., Sardella, G., van Mieghem, N. M., Kim, C. J., Meliga, E., Feng, Y., …, & Mehran, R. (2025). Clinical Outcomes According to the Extent of Atherosclerotic Disease in Female Patients Undergoing Transcatheter Aortic Valve Replacement: An Analysis From the WIN‐TAVI Registry. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31395

Vancouver

Bay B, Gitto M, Sartori S, Vogel B, Tchetche D, Petronio AS, et al. Clinical Outcomes According to the Extent of Atherosclerotic Disease in Female Patients Undergoing Transcatheter Aortic Valve Replacement: An Analysis From the WIN‐TAVI Registry. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31395

BibTeX
@article{Bay2025,
  author = {Bay, Benjamin and Gitto, Mauro and Sartori, Samantha and Vogel, Birgit and Tchetche, Didier and Petronio, Anna Sonia and Mehilli, Julinda and Di Muro, Francesca Maria and Lefevre, Thierry and Presbitero, Patrizia and Capranzano, Piera and Oliva, Angelo and Iadanza, Alessandro and Leone, Pier Pasquale and Sardella, Gennaro and van Mieghem, Nicolas M and Kim, Chan Joon and Meliga, Emanuele and Feng, Yihan and Dumonteil, Nicolas and Fraccaro, Chiara and Trabattoni, Daniela and Mikhail, Ghada and Ferrer-Gracia, Maria-Cruz and Naber, Christoph and Sharma, Samin K and Watanabe, Yusuke and Morice, Marie-Claude and Dangas, George D and Chieffo, Alaide and Mehran, Roxana},
  title = {Clinical Outcomes According to the Extent of Atherosclerotic Disease in Female Patients Undergoing Transcatheter Aortic Valve Replacement: An Analysis From the WIN‐TAVI Registry},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.31395}
}
Start for free →